Skip to main content
S&P 5007,605.41+0.26%DOW52,031.40-0.12%NASDAQ26,149.03+0.64%BTC$75,705.00-0.76%ETH$2,389.42-1.19%GOLD$4,387.70+1.27%OIL$102.69-2.97%
Smart Investors Daily
NT

NASDAQ · NTHI

NEONC TECHNOLOGIES HOLDINGS, INC.

Healthcare · Biotechnology

$3.31

Down-$0.47 (-12.43%)

Updated Sep 16, 2026, 4:09 AM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
181.31M
P/E ratio
-3.28
Dividend yield
0.00%
52-week range
$3.01 – $12.99
Volume
285.99K
Avg. volume
77.82K

Price performance

NTHI price history

1M range · 20 trading sessions · Daily adjusted prices

NTHI closed at $3.31 after 20 trading sessions, down 40.14% for the selected period.

Last close
$3.31
Period change
-40.14%
Period low
$3.31
Period high
$5.53
Daily close
View OHLC price history
NTHI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$3.80$3.80$3.20$3.31285.99K
Sep 14, 2026$3.82$4.00$3.685$3.78290.51K
Sep 11, 2026$3.69$3.72$3.45$3.68188.72K
Sep 10, 2026$3.75$3.78$3.56$3.66131.77K
Sep 9, 2026$4.00$4.00$3.46$3.62299.19K
Sep 8, 2026$4.99$5.02$3.92$4.07417.5K
Sep 4, 2026$4.76$5.195$4.74$5.03102.43K
Sep 3, 2026$4.97$5.14$4.66$4.79142.01K
Sep 2, 2026$4.71$5.10$4.71$4.96151.33K
Sep 1, 2026$4.90$4.94$4.64$4.7396.55K
Aug 31, 2026$4.74$5.07$4.60$4.94174.63K
Aug 28, 2026$4.57$4.75$4.51$4.69100.68K
Aug 27, 2026$4.60$4.76$4.47$4.605101.55K
Aug 26, 2026$4.68$4.77$4.48$4.56119.91K
Aug 25, 2026$4.62$4.9427$4.52$4.71162.55K
Aug 24, 2026$4.84$5.0967$4.55$4.69204.45K
Aug 21, 2026$4.61$4.8899$4.39$4.675167.74K
Aug 20, 2026$4.56$4.7102$4.3183$4.56190.28K
Aug 19, 2026$5.53$5.70$4.54$4.63400.19K
Aug 18, 2026$4.87$5.82$4.85$5.53319.75K

Latest NTHI news

The latest Smart Investors Daily articles mentioning NTHI.

Stock researchCompany · Overview

NTHI research

Overview

Company profile and research snapshot.

Company profile

NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
NTHI recent ratings
DateFirmRatingTarget
Sep 8, 2026BTIGBuy—
May 26, 2026BTIGBuy—
May 19, 2026Alliance Global PartnersBuy—
May 18, 2026Maxim GroupBuy—
Apr 24, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

NeOnc Technologies Holdings, Inc. Announces Pricing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules with New and Existing Institutional Investors

The gross proceeds to the Company from the registered direct offering are estimated to be approximately $15 million before deducting the placement agent’s fees and other estimated offering expenses. The offering is expected to close on or about September 10, 2026, subject to the satisfaction of customary closing conditions.

Yahoo · Aug 13, 2026

Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26

Dallas, Texas--(Newsfile Corp. - August 13, 2026) - NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). 2Q26 meaningfully improves the clinical setup for NTHI, with NEO100 delivering a positive Phase 2a readout and NEO212 gaining regulatory clarity. NEO100 met its primary endpoint with six-month PFS of 48.9% by RANO 2.0 using Kaplan-Meier estimation versus a pre-specified 20% benchmark...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By